Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Matsuno A, Murakami M, Hoya K, Yamada SM, Miyamoto S, Yamada S, Son JH, Nishido H, Ide F, Nagashima H, Sugaya M, Hirohata T, Mizutani A, Okinaga H, Ishii Y, Tahara S, Teramoto A, Osamura RY.

Med Mol Morphol. 2014 Mar;47(1):1-7. doi: 10.1007/s00795-013-0050-z. Review.

PMID:
23955641
2.

DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors.

Hirohata T, Asano K, Ogawa Y, Takano S, Amano K, Isozaki O, Iwai Y, Sakata K, Fukuhara N, Nishioka H, Yamada S, Fujio S, Arita K, Takano K, Tominaga A, Hizuka N, Ikeda H, Osamura RY, Tahara S, Ishii Y, Kawamata T, Shimatsu A, Teramoto A, Matsuno A.

J Clin Endocrinol Metab. 2013 Mar;98(3):1130-6. doi: 10.1210/jc.2012-2924.

PMID:
23365123
3.

Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.

Bengtsson D, Schrøder HD, Andersen M, Maiter D, Berinder K, Feldt Rasmussen U, Rasmussen ÅK, Johannsson G, Hoybye C, van der Lely AJ, Petersson M, Ragnarsson O, Burman P.

J Clin Endocrinol Metab. 2015 Apr;100(4):1689-98. doi: 10.1210/jc.2014-4350.

PMID:
25646794
4.

The role of temozolomide in the treatment of aggressive pituitary tumors.

Liu JK, Patel J, Eloy JA.

J Clin Neurosci. 2015 Jun;22(6):923-9. doi: 10.1016/j.jocn.2014.12.007. Review.

PMID:
25772801
5.

A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report.

Murakami M, Mizutani A, Asano S, Katakami H, Ozawa Y, Yamazaki K, Ishida Y, Takano K, Okinaga H, Matsuno A.

Neurosurgery. 2011 Jun;68(6):E1761-7; discussion E1767. doi: 10.1227/NEU.0b013e318217161a.

PMID:
21389894
6.

MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.

Salehi F, Scheithauer BW, Kros JM, Lau Q, Fealey M, Erickson D, Kovacs K, Horvath E, Lloyd RV.

J Neurooncol. 2011 Sep;104(3):647-57. doi: 10.1007/s11060-011-0532-6.

PMID:
21311951
7.

O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?

Widhalm G, Wolfsberger S, Preusser M, Woehrer A, Kotter MR, Czech T, Marosi C, Knosp E.

Cancer. 2009 Mar 1;115(5):1070-80. doi: 10.1002/cncr.24053.

8.

Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature.

Annamalai AK, Dean AF, Kandasamy N, Kovacs K, Burton H, Halsall DJ, Shaw AS, Antoun NM, Cheow HK, Kirollos RW, Pickard JD, Simpson HL, Jefferies SJ, Burnet NG, Gurnell M.

Pituitary. 2012 Sep;15(3):276-87. doi: 10.1007/s11102-011-0363-7. Review.

PMID:
22076588
9.

Temozolomide in aggressive pituitary adenomas and carcinomas.

Ortiz LD, Syro LV, Scheithauer BW, Rotondo F, Uribe H, Fadul CE, Horvath E, Kovacs K.

Clinics (Sao Paulo). 2012;67 Suppl 1:119-23. Review.

10.

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.

McCormack AI, Wass JA, Grossman AB.

Eur J Clin Invest. 2011 Oct;41(10):1133-48. doi: 10.1111/j.1365-2362.2011.02520.x.

PMID:
21496012
11.

Treatment of pituitary neoplasms with temozolomide: a review.

Syro LV, Ortiz LD, Scheithauer BW, Lloyd R, Lau Q, Gonzalez R, Uribe H, Cusimano M, Kovacs K, Horvath E.

Cancer. 2011 Feb 1;117(3):454-62. doi: 10.1002/cncr.25413. Review.

12.

Disulfiram sensitizes pituitary adenoma cells to temozolomide by regulating O6-methylguanine-DNA methyltransferase expression.

Zhao Y, Xiao Z, Chen W, Yang J, Li T, Fan B.

Mol Med Rep. 2015 Aug;12(2):2313-22. doi: 10.3892/mmr.2015.3664.

PMID:
25937029
13.

Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.

Losa M, Mazza E, Terreni MR, McCormack A, Gill AJ, Motta M, Cangi MG, Talarico A, Mortini P, Reni M.

Eur J Endocrinol. 2010 Dec;163(6):843-51. doi: 10.1530/EJE-10-0629.

14.

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

Raverot G, Sturm N, de Fraipont F, Muller M, Salenave S, Caron P, Chabre O, Chanson P, Cortet-Rudelli C, Assaker R, Dufour H, Gaillard S, François P, Jouanneau E, Passagia JG, Bernier M, Cornélius A, Figarella-Branger D, Trouillas J, Borson-Chazot F, Brue T.

J Clin Endocrinol Metab. 2010 Oct;95(10):4592-9. doi: 10.1210/jc.2010-0644.

PMID:
20660056
15.

Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.

Curtò L, Torre ML, Ferraù F, Pitini V, Altavilla G, Granata F, Longo M, Hofland LJ, Trimarchi F, Cannavò S.

ScientificWorldJournal. 2010 Nov 4;10:2132-8. doi: 10.1100/tsw.2010.210. Review.

16.

Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.

Hagen C, Schroeder HD, Hansen S, Hagen C, Andersen M.

Eur J Endocrinol. 2009 Oct;161(4):631-7. doi: 10.1530/EJE-09-0389.

17.

MGMT immunoexpression in growth hormone-secreting pituitary adenomas and its correlation with Ki-67 labeling index and cytokeratin distribution pattern.

Zuhur SS, Tanik C, Karaman Ö, Velet S, Çil E, Öztürk FY, Özkayalar H, Müslüman AM, Altuntaş Y.

Endocrine. 2011 Oct;40(2):222-7. doi: 10.1007/s12020-011-9485-y.

PMID:
21792693
18.

MGMT immunoexpression in silent subtype 3 pituitary adenomas: possible therapeutic implications.

Fealey ME, Scheithauer BW, Horvath E, Erickson D, Kovacs K, McLendon R, Lloyd RV.

Endocr Pathol. 2010 Sep;21(3):161-5. doi: 10.1007/s12022-010-9120-0.

PMID:
20480258
19.

Aggressive silent corticotroph adenoma progressing to pituitary carcinoma: the role of temozolomide therapy.

Moshkin O, Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Uribe H, Gonzalez R, Cusimano M, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2011 Apr-Jun;10(2):162-7.

20.

Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.

Syro LV, Scheithauer BW, Ortiz LD, Fadul CE, Horvath E, Rotondo F, Kovacs K.

Hormones (Athens). 2009 Oct-Dec;8(4):303-6.

Supplemental Content

Support Center